ORGO - Organogenesis Holdings Inc Stock Price, Fair Value and News

$2.90-0.07 (-2.36%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ORGO Price Action

Last 7 days

-4.2%

Last 30 days

2.8%

Last 90 days

-1.7%

Trailing 12 Months

34.4%

ORGO RSI Chart

ORGO Valuation

Market Cap

393.7M

Price/Earnings (Trailing)

-23.8

Price/Sales (Trailing)

0.88

EV/EBITDA

303.24

Price/Free Cashflow

46.22

ORGO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ORGO Fundamentals

ORGO Revenue

Revenue (TTM)

448.4M

Rev. Growth (Yr)

11.01%

Rev. Growth (Qtr)

18.42%

ORGO Earnings

Earnings (TTM)

-16.5M

Earnings Growth (Yr)

-420.6%

Earnings Growth (Qtr)

-711.57%

ORGO Profitability

Operating Margin

75.14%

EBT Margin

-2.91%

Return on Equity

-6.28%

Return on Assets

-3.73%

Free Cashflow Yield

2.16%

ORGO Investor Care

Shares Dilution (1Y)

0.96%

Diluted EPS (TTM)

-0.13

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	435.5M	448.4M	0	0
2023	461.4M	457.3M	449.0M	433.1M
2022	461.9M	460.1M	463.2M	450.9M
2021	379.1M	433.4M	446.3M	467.4M
2020	422.4M	426.5M	463.0M	338.3M
2019	215.0M	236.4M	249.9M	417.8M
2018	194.2M	183.7M	183.0M	193.4M
2017	153.7M	168.6M	183.6M	198.5M
2016	0	0	0	138.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About Organogenesis Holdings Inc

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary wound covering; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly AM, PuraPly XT, and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

CEO	Mr. Gary S. Gillheeney Sr.
WEBSITE	https://organogenesis.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	1030

Organogenesis Holdings Inc Frequently Asked Questions

What is the ticker symbol for Organogenesis Holdings Inc? What does ORGO stand for in stocks?

ORGO is the stock ticker symbol of Organogenesis Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Organogenesis Holdings Inc (ORGO)?

As of Tue Oct 29 2024, market cap of Organogenesis Holdings Inc is 393.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORGO stock?

You can check ORGO's fair value in chart for subscribers.

Is Organogenesis Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether ORGO is over valued or under valued. Whether Organogenesis Holdings Inc is cheap or expensive depends on the assumptions which impact Organogenesis Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORGO.

What is Organogenesis Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 29 2024, ORGO's PE ratio (Price to Earnings) is -23.8 and Price to Sales (PS) ratio is 0.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORGO PE ratio will change depending on the future growth rate expectations of investors.